An enzyme immunoassay for determining plasma concentrations of didemnin B
Didemnin A was conjugated at the amino terminus of the N‐methylleucine residue, via the linkers N‐succinimidyl‐3‐(2‐pyridyldithio)propionate and trans‐1,4‐maleimidomethylcyclohexane carboxylic acid, to keyhole limpet hemocyanin (KLH) and bovine serum albumin (BSA). The didemnin‐KLH conjugates were u...
Gespeichert in:
| Veröffentlicht in: | Journal of clinical laboratory analysis 1992, Vol.6 (3), p.136-142 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 142 |
|---|---|
| container_issue | 3 |
| container_start_page | 136 |
| container_title | Journal of clinical laboratory analysis |
| container_volume | 6 |
| creator | Raybould, T. J. G. Grothaus, P. G. Simpson, Samantha B. Bignami, G. S. Lazo, Carolyn B. Newman, R. A. |
| description | Didemnin A was conjugated at the amino terminus of the N‐methylleucine residue, via the linkers N‐succinimidyl‐3‐(2‐pyridyldithio)propionate and trans‐1,4‐maleimidomethylcyclohexane carboxylic acid, to keyhole limpet hemocyanin (KLH) and bovine serum albumin (BSA). The didemnin‐KLH conjugates were used to hyperimmunize rabbits. The resulting high titer antisera were employed with didemnin‐BSA conjugate‐coated microtiter plate wells to develop an indirect competitive inhibition enzyme immunoassay (CIEIA) that was fully cross reactive with didemnin B. A CIEIA is described that is capable of detecting the drug in plasma from didemnin Btreated patients at concentrations down to 1‐3 ng/ml. This simple, sensitive CIEIA has been employed to demonstrate plasma drug clearance profiles with samples from didemnin B‐treated patients. © 1992 Wiley‐Liss, Inc. |
| doi_str_mv | 10.1002/jcla.1860060307 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_73151322</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>16293275</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4137-da76d3042e3b5a75da70db80040a447d5fee8732225d7d4a5808e2ce35a90b2d3</originalsourceid><addsrcrecordid>eNqFkE1P3DAURa2qiA60664qedVdhmc7jh11NYzKl0YgIap2Z3nil8o0dgY7ozL8eoKCQKxYPT3dc-_iEPKVwZwB8KPbprNzpiuACgSoD2TGoNYF11x-JDPQWhUamPhEDnK-BQBds2qf7DMJVa1hRs4XkWJ82AWkPoRt7G3OdkfbPlGHA6bgo49_6aazOVja9LHBOCQ7-D5m2rfUeYdhROjxZ7LX2i7jl-d7SH6d_LxZnhWrq9Pz5WJVNCUTqnBWVU5AyVGspVVy_MGtNUAJtiyVky2iVoJzLp1ypZUaNPIGhbQ1rLkTh-T7tLtJ_d0W82CCzw12nY3Yb7NRgkk29t8FWcVrwZUcwaMJbFKfc8LWbJIPNu0MA_Nk2TxZNq-Wx8a35-ntOqB75SetY_5jyv_7DnfvzZmL5WrxZr2Y2j4PeP_StumfqZRQ0vy-PDV_Rps3enVtLsUj5DSYZA</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>16293275</pqid></control><display><type>article</type><title>An enzyme immunoassay for determining plasma concentrations of didemnin B</title><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Raybould, T. J. G. ; Grothaus, P. G. ; Simpson, Samantha B. ; Bignami, G. S. ; Lazo, Carolyn B. ; Newman, R. A.</creator><creatorcontrib>Raybould, T. J. G. ; Grothaus, P. G. ; Simpson, Samantha B. ; Bignami, G. S. ; Lazo, Carolyn B. ; Newman, R. A.</creatorcontrib><description>Didemnin A was conjugated at the amino terminus of the N‐methylleucine residue, via the linkers N‐succinimidyl‐3‐(2‐pyridyldithio)propionate and trans‐1,4‐maleimidomethylcyclohexane carboxylic acid, to keyhole limpet hemocyanin (KLH) and bovine serum albumin (BSA). The didemnin‐KLH conjugates were used to hyperimmunize rabbits. The resulting high titer antisera were employed with didemnin‐BSA conjugate‐coated microtiter plate wells to develop an indirect competitive inhibition enzyme immunoassay (CIEIA) that was fully cross reactive with didemnin B. A CIEIA is described that is capable of detecting the drug in plasma from didemnin Btreated patients at concentrations down to 1‐3 ng/ml. This simple, sensitive CIEIA has been employed to demonstrate plasma drug clearance profiles with samples from didemnin B‐treated patients. © 1992 Wiley‐Liss, Inc.</description><identifier>ISSN: 0887-8013</identifier><identifier>EISSN: 1098-2825</identifier><identifier>DOI: 10.1002/jcla.1860060307</identifier><identifier>PMID: 1506980</identifier><language>eng</language><publisher>New York: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>antibodies ; Antineoplastic Agents - blood ; Antineoplastic Agents - immunology ; Antineoplastic Agents - therapeutic use ; aquatic drugs ; blood ; cancer ; concentration ; cyclic peptides ; Depsipeptides ; didemnin B ; didemnin concentrations ; didemnins ; ELISA ; enzyme immunoassay ; Evaluation Studies as Topic ; Haptens ; Hemocyanins ; Humans ; Immunoenzyme Techniques ; Marine ; medicine ; Neoplasms - blood ; Neoplasms - drug therapy ; Peptides, Cyclic - blood ; Peptides, Cyclic - immunology ; Peptides, Cyclic - therapeutic use ; pharmacology ; plasma ; Serum Albumin, Bovine ; Trididemnum solidum</subject><ispartof>Journal of clinical laboratory analysis, 1992, Vol.6 (3), p.136-142</ispartof><rights>Copyright © 1992 Wiley Periodicals, Inc., A Wiley Company</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4137-da76d3042e3b5a75da70db80040a447d5fee8732225d7d4a5808e2ce35a90b2d3</citedby><cites>FETCH-LOGICAL-c4137-da76d3042e3b5a75da70db80040a447d5fee8732225d7d4a5808e2ce35a90b2d3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fjcla.1860060307$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fjcla.1860060307$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,780,784,1416,4014,27914,27915,27916,45565,45566</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/1506980$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Raybould, T. J. G.</creatorcontrib><creatorcontrib>Grothaus, P. G.</creatorcontrib><creatorcontrib>Simpson, Samantha B.</creatorcontrib><creatorcontrib>Bignami, G. S.</creatorcontrib><creatorcontrib>Lazo, Carolyn B.</creatorcontrib><creatorcontrib>Newman, R. A.</creatorcontrib><title>An enzyme immunoassay for determining plasma concentrations of didemnin B</title><title>Journal of clinical laboratory analysis</title><addtitle>J. Clin. Lab. Anal</addtitle><description>Didemnin A was conjugated at the amino terminus of the N‐methylleucine residue, via the linkers N‐succinimidyl‐3‐(2‐pyridyldithio)propionate and trans‐1,4‐maleimidomethylcyclohexane carboxylic acid, to keyhole limpet hemocyanin (KLH) and bovine serum albumin (BSA). The didemnin‐KLH conjugates were used to hyperimmunize rabbits. The resulting high titer antisera were employed with didemnin‐BSA conjugate‐coated microtiter plate wells to develop an indirect competitive inhibition enzyme immunoassay (CIEIA) that was fully cross reactive with didemnin B. A CIEIA is described that is capable of detecting the drug in plasma from didemnin Btreated patients at concentrations down to 1‐3 ng/ml. This simple, sensitive CIEIA has been employed to demonstrate plasma drug clearance profiles with samples from didemnin B‐treated patients. © 1992 Wiley‐Liss, Inc.</description><subject>antibodies</subject><subject>Antineoplastic Agents - blood</subject><subject>Antineoplastic Agents - immunology</subject><subject>Antineoplastic Agents - therapeutic use</subject><subject>aquatic drugs</subject><subject>blood</subject><subject>cancer</subject><subject>concentration</subject><subject>cyclic peptides</subject><subject>Depsipeptides</subject><subject>didemnin B</subject><subject>didemnin concentrations</subject><subject>didemnins</subject><subject>ELISA</subject><subject>enzyme immunoassay</subject><subject>Evaluation Studies as Topic</subject><subject>Haptens</subject><subject>Hemocyanins</subject><subject>Humans</subject><subject>Immunoenzyme Techniques</subject><subject>Marine</subject><subject>medicine</subject><subject>Neoplasms - blood</subject><subject>Neoplasms - drug therapy</subject><subject>Peptides, Cyclic - blood</subject><subject>Peptides, Cyclic - immunology</subject><subject>Peptides, Cyclic - therapeutic use</subject><subject>pharmacology</subject><subject>plasma</subject><subject>Serum Albumin, Bovine</subject><subject>Trididemnum solidum</subject><issn>0887-8013</issn><issn>1098-2825</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>1992</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1P3DAURa2qiA60664qedVdhmc7jh11NYzKl0YgIap2Z3nil8o0dgY7ozL8eoKCQKxYPT3dc-_iEPKVwZwB8KPbprNzpiuACgSoD2TGoNYF11x-JDPQWhUamPhEDnK-BQBds2qf7DMJVa1hRs4XkWJ82AWkPoRt7G3OdkfbPlGHA6bgo49_6aazOVja9LHBOCQ7-D5m2rfUeYdhROjxZ7LX2i7jl-d7SH6d_LxZnhWrq9Pz5WJVNCUTqnBWVU5AyVGspVVy_MGtNUAJtiyVky2iVoJzLp1ypZUaNPIGhbQ1rLkTh-T7tLtJ_d0W82CCzw12nY3Yb7NRgkk29t8FWcVrwZUcwaMJbFKfc8LWbJIPNu0MA_Nk2TxZNq-Wx8a35-ntOqB75SetY_5jyv_7DnfvzZmL5WrxZr2Y2j4PeP_StumfqZRQ0vy-PDV_Rps3enVtLsUj5DSYZA</recordid><startdate>1992</startdate><enddate>1992</enddate><creator>Raybould, T. J. G.</creator><creator>Grothaus, P. G.</creator><creator>Simpson, Samantha B.</creator><creator>Bignami, G. S.</creator><creator>Lazo, Carolyn B.</creator><creator>Newman, R. A.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><scope>BSCLL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QL</scope><scope>8FD</scope><scope>C1K</scope><scope>F1W</scope><scope>FR3</scope><scope>H95</scope><scope>L.G</scope><scope>M81</scope><scope>P64</scope><scope>7X8</scope></search><sort><creationdate>1992</creationdate><title>An enzyme immunoassay for determining plasma concentrations of didemnin B</title><author>Raybould, T. J. G. ; Grothaus, P. G. ; Simpson, Samantha B. ; Bignami, G. S. ; Lazo, Carolyn B. ; Newman, R. A.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4137-da76d3042e3b5a75da70db80040a447d5fee8732225d7d4a5808e2ce35a90b2d3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>1992</creationdate><topic>antibodies</topic><topic>Antineoplastic Agents - blood</topic><topic>Antineoplastic Agents - immunology</topic><topic>Antineoplastic Agents - therapeutic use</topic><topic>aquatic drugs</topic><topic>blood</topic><topic>cancer</topic><topic>concentration</topic><topic>cyclic peptides</topic><topic>Depsipeptides</topic><topic>didemnin B</topic><topic>didemnin concentrations</topic><topic>didemnins</topic><topic>ELISA</topic><topic>enzyme immunoassay</topic><topic>Evaluation Studies as Topic</topic><topic>Haptens</topic><topic>Hemocyanins</topic><topic>Humans</topic><topic>Immunoenzyme Techniques</topic><topic>Marine</topic><topic>medicine</topic><topic>Neoplasms - blood</topic><topic>Neoplasms - drug therapy</topic><topic>Peptides, Cyclic - blood</topic><topic>Peptides, Cyclic - immunology</topic><topic>Peptides, Cyclic - therapeutic use</topic><topic>pharmacology</topic><topic>plasma</topic><topic>Serum Albumin, Bovine</topic><topic>Trididemnum solidum</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Raybould, T. J. G.</creatorcontrib><creatorcontrib>Grothaus, P. G.</creatorcontrib><creatorcontrib>Simpson, Samantha B.</creatorcontrib><creatorcontrib>Bignami, G. S.</creatorcontrib><creatorcontrib>Lazo, Carolyn B.</creatorcontrib><creatorcontrib>Newman, R. A.</creatorcontrib><collection>Istex</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>Technology Research Database</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ASFA: Aquatic Sciences and Fisheries Abstracts</collection><collection>Engineering Research Database</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) 1: Biological Sciences & Living Resources</collection><collection>Aquatic Science & Fisheries Abstracts (ASFA) Professional</collection><collection>Biochemistry Abstracts 3</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of clinical laboratory analysis</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Raybould, T. J. G.</au><au>Grothaus, P. G.</au><au>Simpson, Samantha B.</au><au>Bignami, G. S.</au><au>Lazo, Carolyn B.</au><au>Newman, R. A.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>An enzyme immunoassay for determining plasma concentrations of didemnin B</atitle><jtitle>Journal of clinical laboratory analysis</jtitle><addtitle>J. Clin. Lab. Anal</addtitle><date>1992</date><risdate>1992</risdate><volume>6</volume><issue>3</issue><spage>136</spage><epage>142</epage><pages>136-142</pages><issn>0887-8013</issn><eissn>1098-2825</eissn><abstract>Didemnin A was conjugated at the amino terminus of the N‐methylleucine residue, via the linkers N‐succinimidyl‐3‐(2‐pyridyldithio)propionate and trans‐1,4‐maleimidomethylcyclohexane carboxylic acid, to keyhole limpet hemocyanin (KLH) and bovine serum albumin (BSA). The didemnin‐KLH conjugates were used to hyperimmunize rabbits. The resulting high titer antisera were employed with didemnin‐BSA conjugate‐coated microtiter plate wells to develop an indirect competitive inhibition enzyme immunoassay (CIEIA) that was fully cross reactive with didemnin B. A CIEIA is described that is capable of detecting the drug in plasma from didemnin Btreated patients at concentrations down to 1‐3 ng/ml. This simple, sensitive CIEIA has been employed to demonstrate plasma drug clearance profiles with samples from didemnin B‐treated patients. © 1992 Wiley‐Liss, Inc.</abstract><cop>New York</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>1506980</pmid><doi>10.1002/jcla.1860060307</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0887-8013 |
| ispartof | Journal of clinical laboratory analysis, 1992, Vol.6 (3), p.136-142 |
| issn | 0887-8013 1098-2825 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_73151322 |
| source | MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | antibodies Antineoplastic Agents - blood Antineoplastic Agents - immunology Antineoplastic Agents - therapeutic use aquatic drugs blood cancer concentration cyclic peptides Depsipeptides didemnin B didemnin concentrations didemnins ELISA enzyme immunoassay Evaluation Studies as Topic Haptens Hemocyanins Humans Immunoenzyme Techniques Marine medicine Neoplasms - blood Neoplasms - drug therapy Peptides, Cyclic - blood Peptides, Cyclic - immunology Peptides, Cyclic - therapeutic use pharmacology plasma Serum Albumin, Bovine Trididemnum solidum |
| title | An enzyme immunoassay for determining plasma concentrations of didemnin B |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-15T06%3A22%3A36IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=An%20enzyme%20immunoassay%20for%20determining%20plasma%20concentrations%20of%20didemnin%20B&rft.jtitle=Journal%20of%20clinical%20laboratory%20analysis&rft.au=Raybould,%20T.%20J.%20G.&rft.date=1992&rft.volume=6&rft.issue=3&rft.spage=136&rft.epage=142&rft.pages=136-142&rft.issn=0887-8013&rft.eissn=1098-2825&rft_id=info:doi/10.1002/jcla.1860060307&rft_dat=%3Cproquest_cross%3E16293275%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=16293275&rft_id=info:pmid/1506980&rfr_iscdi=true |